Amphastar Pharmaceuticals, Inc. (29A.F)

28,20 +0,80 (+2,92%) Börsenschluss: 08:14AM CET

Amphastar Pharmaceuticals, Inc.

11570 6th Street
Rancho Cucamonga, CA 91730
United States
909 980 9484
https://www.amphastar.com

Sektor(en): Healthcare
Branche: Drug Manufacturers—Specialty & Generic
Vollzeitmitarbeiter: 1.761

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Ziping Luo Ph.D.	Chairman, Chief Scientist & COO	1,34M	N/A	1950
Dr. Yongfeng Zhang Ph.D.	Co-Founder, Pres, CEO, Chief Scientific Officer & Director	1,93M	N/A	1947
Mr. William J. Peters M.B.A.	CFO, Exec. VP of Fin., Treasurer & Director	1,11M	360,51k	1968
Mr. Jacob Liawatidewi M.B.A.	Exec. VP of Sales, Marketing & Corp. Admin. Center, Corp. Sec. and Director	773,69k	425,05k	1974
Mr. Rong Zhou M.S.	Exec. VP of Production Center	842,77k	374,26k	1959
Dan Dischner M.B.A.	VP of HR & Corp. Communication	N/A	N/A	N/A
Tony Marrs M.B.A., M.P.H.	Sr. VP of Regulatory Affairs & Clinical Operations	N/A	N/A	N/A
Mr. Peter Langosh	VP of Operational Improvement and VP of Internal Audit	N/A	N/A	1953

Die Beträge haben den Stand 31. Dezember 2021 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Amphastar Pharmaceuticals, Inc., a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and API. It offers Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, a low molecular weight heparin to prevent and treat deep vein thrombosis; Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, a lyophilized powder for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency. The company also provides Amphadase, a bovine-sourced hyaluronidase injection to absorb and disperse other injected drugs; Epinephrine injection for the emergency treatment of allergic reactions; lidocaine jelly, an anesthetic product for urological procedures; lidocaine topical solution for various procedures; phytonadione injection, a vitamin K1 injection for newborn babies; emergency syringe products for emergency use in hospital settings; morphine injection for use with patient controlled analgesia pumps; and lorazepam injection for surgery and medical procedures. In addition, it offers neostigmine methylsulfate injection to treat myasthenia gravis and to reverse the effects of muscle relaxants; and Isoproterenol hydrochloride injection for mild or transient episodes of heart block. Further, the company distributes recombinant human insulin active pharmaceutical ingredients (API) and porcine insulin API. It serves hospitals, care facilities, alternate care sites, clinics, and doctors' offices. The company was founded in 1996 and is headquartered in Rancho Cucamonga, California.

Corporate Governance

Amphastar Pharmaceuticals, Inc.s ISS Governance QualityScore, Stand 1. Februar 2023, lautet 6. Die grundlegenden Scores sind Audit: 1, Vorstand: 10, Shareholderrechte: 5, Kompensation: 5.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.